Fulgent Genetics Inc

FLGT remains in a Stage 2 advancing phase with a bullish medium-term bias supported by the active Lockout Rally continuation pattern. Price is currently in a corrective pullback into the 9/21 EMA zone above the rising 50-day MA, offering a disciplined entry point. No short-term exhaustion or overbought stress is visible in the neutral OB/OS context. The speculative strategy demands high selectivity, justifying a Buy Now on shallow pullback acceptance in the EMA zone.

• ↑Precision diagnostics segment up 17.8% YoY, adding $6.7M revenue
• ↑Bako & StrataDX deals to contribute ~$50–55M top-line in 2026
• ↓Loss of largest customer will reduce revenue by ~$59M in 2026